Arla Foods Ingredients has launched commercial production of its pure BLG (beta-lactoglobulin) product, Lacprodan BLG-100.
Produced at the company’s Foods Ingredients Innovation centre, the product is a pure BLG ingredient created using a patented separation technology, contains 45% more leucine (the main muscle-building amino acid) than commercially available whey protein isolates, the company claims.
The product is suitable for applications in medical nutrition and sports nutrition.
The product’s high leucine content means it can support muscle protein synthesis to minimise the loss of muscle mass and sustain physical mobility, which is a key requirement for patients and elderly people.
It is also low in minerals, especially phosphorous, making it suitable for patients with kidney problems.
The ingredient enables protein concentrations as high as 23% in ready-to-drink serving sizes. Its medical and sports nutrition applications include clear ready-to-drink formats and translucent high-protein shots.
In addition to its naturally high leucine content, the company claims, it provides 26% more essential amino acids and 40% more branched-chain amino acids than commercially available whey protein.
The company has applied for Lacprodan BLG-100 to become authorised as a novel food in the EU.